|
Transplantation
Citations 41-50 of 1455 total displayed.
|
Past content
(since Jan 1997):
|
Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ regulatory T cells
- Christian Becker, Christian Taube, Tobias Bopp, Christoph Becker, Kai Michel, Jan Kubach, Sebastian Reuter, Nina Dehzad, Markus F. Neurath, Kurt Reifenberg, Franz-Joseph Schneider, Edgar Schmitt, and Helmut Jonuleit
Blood 2009; 114: 1263-1269.
[Abstract]
[Full text]
[PDF]
Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation
- Simone Cunha Maradei, Angelo Maiolino, Alexandre Mello de Azevedo, Marta Colares, Luis Fernando Bouzas, and Marcio Nucci
Blood 2009; 114: 1270-1275.
[Abstract]
[Full text]
[PDF]
Characterization in vitro and engraftment potential in vivo of human progenitor T cells generated from hematopoietic stem cells
- Génève Awong, Elaine Herer, Charles D. Surh, John E. Dick, Ross N. La Motte-Mohs, and Juan Carlos Zúñiga-Pflücker
Blood 2009; 114: 972-982.
[Abstract]
[Full text]
[PDF]
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
- Holbrook E. Kohrt, Brit B. Turnbull, Kartoosh Heydari, Judith A. Shizuru, Ginna G. Laport, David B. Miklos, Laura J. Johnston, Sally Arai, Wen-Kai Weng, Richard T. Hoppe, Philip W. Lavori, Karl G. Blume, Robert S. Negrin, Samuel Strober, and Robert Lowsky
Blood 2009; 114: 1099-1109.
[Abstract]
[Full text]
[PDF]
Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease
- Xiao Chen, Rupali Das, Richard Komorowski, Amy Beres, Martin J. Hessner, Masahiko Mihara, and William R. Drobyski
Blood 2009; 114: 891-900.
[Abstract]
[Full text]
[PDF]
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network
- Amin M. Alousi, Daniel J. Weisdorf, Brent R. Logan, Javier Bolaños-Meade, Shelly Carter, Nancy DiFronzo, Marcelo Pasquini, Steven C. Goldstein, Vincent T. Ho, Brandon Hayes-Lattin, John R. Wingard, Mary M. Horowitz, and John E. Levine, on behalf of the Blood and Marrow Transplant Clinical Trials Network
Blood 2009; 114: 511-517.
[Abstract]
[Full text]
[PDF]
Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector
- Ali Ramezani and Robert G. Hawley
Blood 2009; 114: 526-534.
[Abstract]
[Full text]
[PDF]
Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation
- Marina T. van Leeuwen, Andrew E. Grulich, Angela C. Webster, Margaret R.E. McCredie, John H. Stewart, Stephen P. McDonald, Janaki Amin, John M. Kaldor, Jeremy R. Chapman, and Claire M. Vajdic
Blood 2009; 114: 630-637.
[Abstract]
[Full text]
[PDF]
Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming
- Steven L. Highfill, Ryan M. Kelly, Matthew J. O'Shaughnessy, Qing Zhou, Lily Xia, Angela Panoskaltsis-Mortari, Patricia A. Taylor, Jakub Tolar, and Bruce R. Blazar
Blood 2009; 114: 693-701.
[Abstract]
[Full text]
[PDF]
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD
- Afonso C. Vigorito, Paulo V. Campregher, Barry E. Storer, Paul A. Carpenter, Carina K. Moravec, Hans-Peter Kiem, Matthew L. Fero, Edus H. Warren, Stephanie J. Lee, Frederick R. Appelbaum, Paul J. Martin, and Mary E. D. Flowers
Blood 2009; 114: 702-708.
[Abstract]
[Full text]
[PDF]
|
|
